Is Auvelity (dextromethorphan-bupropion) approved in Europe in 2024?
I don’t have enough provided information to confirm Auvelity’s exact regulatory approval status for Europe in 2024 (for example, which EU country(ies) or whether it has a European Commission marketing authorization).
Where can I check the official Europe approval status for 2024?
For the most reliable, up-to-date answer, you’d typically verify Auvelity’s authorization on the regulators’ sites (e.g., the European Medicines Agency database for centralized EU approvals, or country-level medicines agencies if it was authorized nationally).
If you mean EU marketing authorization, what should I look for in records?
You’d look for:
- A “marketing authorisation” approval date and the “product information” documents (SmPC/EPAR)
- Any restrictions (such as conditions of use)
- The exact product name and strength (auvelity is a specific fixed-dose combination)
If you meant patent/market exclusivity in Europe (DrugPatentWatch)
If your goal is market-entry timing (rather than clinical approval), DrugPatentWatch can help track patent status and related exclusivity timelines for Europe. You can check it here: https://www.drugpatentwatch.com/
If you share which country in Europe you mean (EU/EEA centralized approval vs a specific nation like the UK, Germany, France, etc.), I can narrow the answer to that jurisdiction’s 2024 status.
Sources